According to “thrilling” and “unprecedented” findings from a ten-year global trial, taking a tablet once a day reduces the risk of dying from lung cancer by half. According to data given at the world’s largest cancer conference, using the medication “osimertinib” after surgery significantly reduced the probability of patients dying by 51%. Lung cancer accounts for over 1.8 million annual deaths worldwide among cancer patients. The findings were presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago and came from a late-stage study directed by Yale University.
“Thirty years ago, there was nothing we could do for these patients,” stated Dr. Roy Herbst, Yale Cancer Centre’s deputy director and lead author of the study. “Now we have this potent drug. Fifty percent is a big deal in any disease, but certainly in a disease like lung cancer, which has typically been very resistant to therapies,” he added.
The drug must become the “standard of care” for at least a quarter of lung cancer patients worldwide who have the EGFR mutation
Patients from 26 different nations, ranging in age from 30 to 86, participated in the Adaura experiment. The research investigates whether the medication helped people with non-small cell lung cancer, the most prevalent form of the deadly disease. Dr. Herbst referred to the outcomes as “thrilling” and stressed earlier research from the same experiment, which demonstrated that the pill also significantly lowers the risk of cancer recurrence.
The drug must become the “standard of care” for at least a quarter of lung cancer patients worldwide who have the EGFR mutation, according to Herbst, who serves as an assistant dean for translational research at Yale School of Medicine. Herbst predicted that the drug will be “practice-changing” and “practice-changing.” Some patients in the UK, the US, and other nations already have access to the medication, but more individuals should gain from it.
“Not everyone diagnosed with lung cancer is tested for the EGFR mutation, which needs to change. This further reinforces the need to identify these patients with available biomarkers at the time of diagnosis and before treatment begins,” stated Herbst, based on the findings of the study. “Adjuvant osimertinib demonstrated an unprecedented, highly statistically significant and clinically meaningful overall survival benefit in patients,” stated the study.
“It is hard to convey how important this finding is and how long it’s taken to get here,” stated Dr. Nathan Pennell, who is an Asco expert and was not involved with the study. “This shows an unequivocal, highly significant improvement in survival,” she added.
